Application Deadline
July 11, 2024


Job description

We are looking for a Junior Scientist and/or Scientist to join our team in planning, conducting, optimizing, and evaluating primarily nucleic acid-based experiments as part of internal technology and RNA-based diagnostic test development.

In this multifaceted role, you will help advance our pipeline of novel nucleic acid detection technologies, solve technical obstacles, test different concepts in the laboratory, read scientific papers, and generate new ideas in collaboration with our innovative R&D team.

The position will be based at the headquarters in Bratislava, Slovakia located at the modern Comenius University Science Park.


  • Performing molecular biology techniques, including nucleic acid extraction/purification, NGS library preparation, nucleic acid quality control, gel electrophoresis, various nucleic acid amplification and visualization techniques etc.
  • Conducting RNA fluorescent in situ hybridization, immunohistochemistry and using fluorescence/brightfield microscopy/confocal microscopy and laser capture microdissection to image and dissect tissue.
  • Performing routine histopathological examination of tissues, including tissue processing/preparation (e.g., paraffin-embedding, microtome sectioning) and histological staining (e.g., hematoxylin and eosin staining).  
  • Alternatively, performing the synthesis, handling, processing and analyzing synthetic oligonucleotides.
  • Documenting and analyzing experimental work.
  • Performing internal quality control of reagents and analytical equipment.


  • Junior scientist level – Bachelor’s degree
  • Scientist level – Master’s degree or PhD
  • Work experience will also be considered.
  • Education in Biology, Molecular Biology, Biochemistry, Biotechnology, Pharmaceutical Sciences, Organic Chemistry or a related field.
  • Experience in one or more of the following is an advantage:some text
    • Biochemical / molecular assay design and troubleshooting.
    • Programming (Python, R, etc.) within the scope of automating simple data transformation-related tasks and creating simple utilities.
    • Gel electrophoresis, solid-phase oligonucleotide synthesis, HPLC purification
  • The ability to work as part of a multidisciplinary team is essential.
  • Strong planning, analytical and systematic troubleshooting skills.
  • Written and oral communication skills in English is preferred (English is our working language).
  • The ideal candidate should be detail-oriented, diligent, adaptable, and capable of working in a fast-paced, flexible environment while always upholding emphasis on quality.

We offer

We offer a great career with development opportunities in a highly motivating and professional environment. You may be looking for a new career path or simply looking to contribute to a small, hard-working organization with the ambition to make a difference.

You will be offered the opportunity to spearhead the next ground-breaking nucleic acid-based detection technologies and diagnostics which will make a difference in real-world clinical settings.

The job will be challenging and rewarding at the same time. You will have world class colleagues, 4-5 weeks of paid holiday, and a salary commensurate to your qualifications (starting from €2000/month). Salary increases by 10% after the trial period.


MultiplexDX is a cutting-edge cancer diagnostic company revolutionizing personalized medicine through innovative molecular diagnostics. Our mission is to improve patient outcomes by providing accurate cancer diagnoses and provide prognostic and predictive treatment signatures, enabling physicians to tailor treatments for optimal results.

For additional information, please contact

Peter Kilian
Ilkovičova 8
84104 Bratislava, Slovakia

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter